Independent Advisor Alliance’s NeuroSense Therapeutics NRSN Stock Holding History

Independent Advisor Alliance’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-5,000	Closed	-$72K	–	1113
2026 Q2	$72K	Buy	5,000 +2,500	+100%	+$39K	﹤0.01%	1020
2026 Q1	$37.8K	Buy	+2,500	New	+$44.7K	﹤0.01%	1569

Other funds holding NRSN

PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Independent Advisor Alliance's NRSN Position: Q3 2026 in Review

Independent Advisor Alliance sold out of NeuroSense Therapeutics (NRSN) in Q3 2026, closing a stake of 5,000 shares — an estimated $72K sold.

Independent Advisor Alliance first reported a position in NRSN in Q1 2026 and held it in 2 quarters. The position peaked at $72K in Q2 2026. 5 funds tracked by Wall St. Rank hold NRSN as of Q3 2026.

Independent Advisor Alliance reported no remaining NeuroSense Therapeutics position as of Q3 2026 after selling out during the quarter.
Independent Advisor Alliance sold 5,000 NeuroSense Therapeutics shares in Q3 2026, an estimated $72K.
Independent Advisor Alliance first reported a position in NeuroSense Therapeutics in Q1 2026 and held it in 2 quarters.
Independent Advisor Alliance's NeuroSense Therapeutics position peaked at $72K in Q2 2026.
5 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2026.

Based on Independent Advisor Alliance's 13F filing for Q3 2026, filed 10 Nov 2026.